Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

How food and alcohol cues leave different signatures in the brain

20

May 2026

How food and alcohol cues leave different signatures in the brain

Food and alcohol cues appear to engage partially distinct EEG oscillatory patterns, with food cues linked mainly to increased delta activity and alcohol-related processing showing alpha and delta differences in key contrasts. The effects were strongest in participants with relatively higher AUDIT scores, but neural changes were small and subjective cue responses were more robust.

Ensitrelvir cuts household COVID-19 risk when given after exposure

20

May 2026

Ensitrelvir cuts household COVID-19 risk when given after exposure

Ensitrelvir, an oral SARS-CoV-2 3C-like protease inhibitor, reduced symptomatic RT-PCR-confirmed COVID-19 among household contacts when given within 72 hours after symptom onset in the infected index patient. In the phase 3 SCORPIO-PEP trial, COVID-19 occurred in 2.9% of ensitrelvir recipients versus 9.0% of placebo recipients, with similar overall adverse-event rates.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.